Frank Verwiel
CIK: 0001545794
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NTLA
Intellia Therapeutics, Inc.
Director
Discretionary Trading P&L
Holdings
About Verwiel Frank
Verwiel Frank (SEC CIK 0001545794) files insider reports with the SEC as Director of Intellia Therapeutics, Inc. (NTLA).
Signal8 holds 2 ownership filings by Verwiel Frank, all Form 4s, filed between Jun 13, 2025 and Jun 10, 2026. Those filings report 2 transactions, from Jun 11, 2025 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Verwiel Frank's filings is in CAMBRIDGE, MA.
Recent filings by Verwiel Frank
Other insiders filing for Intellia Therapeutics, Inc. (NTLA)
- Marantz Jing L., EVP, Chief Medical Officer
- Dube Michael P, VP, Chief Accounting Officer
- LEONARD JOHN M, President and CEO
- Dulac Edward J III, EVP, Chief Financial Officer
- Keresty Georgia, Director
- GOODMAN JESSE, Director